NEWS

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership

Dec 07, 2020

Fibronostics US INC, receives CE (Conformité Européenne) mark approval for the product LIVERFASt™

Dec 01, 2020

AASLD Poster: LIVERFASt is detecting and discriminant different phases of liver disease, with better performances than APRI or FIB-4.

Nov 25, 2020

Fatty Liver Foundation featuring LIVERFASt™.

Nov 23, 2020

AASLD Poster: Comparative performance of LIVERFASt™, Fibroscan and other non-invasive test for Severe Fibrosis in NAFLD Patients.

Nov 21, 2020

Non-Invasive testing for NASH at the AASLD Liver Meeting.

Nov 09, 2020

LIVERFASt™ provides the right diagnosis of liver disease conditions in type 2 diabetes patients.

Nov 01, 2020

Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding.

Aug 24, 2020

Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series.

Aug 21, 2020

Sought-after Hepatology and Gastroenterology expert, Prof. Stephen A. Harrison MD joins Fibronostics’ Advisory Board.

Aug 05, 2020

LIVERFASt screening and diagnostics capabilities combines with Health Catalyst National Registry power up a COVID19 study.

Jun 08, 2020

Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel.

Aug 21, 2020

Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool.

Aug 05, 2020

When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao.

Jun 08, 2020

Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for.

Aug 21, 2020